Document:

Exhibit
4.1

 

NEITHER
THIS NOTE NOR THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY
APPLICABLE STATE SECURITIES LAW, AND NO INTEREST HEREIN OR THEREIN MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED OR OTHERWISE
TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT AND APPLICABLE STATE SECURITIES LAWS COVERING ANY
SUCH TRANSACTION, (B) THE COMPANY RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF SUCH SECURITIES (CONCURRED IN BY COUNSEL FOR THE COMPANY)
THAT SUCH TRANSACTION IS EXEMPT FROM REGISTRATION, OR (C) THE COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM
REGISTRATION.

 

THERALINK
TECHNOLOGIES, INC.

 

2021
CONVERTIBLE PROMISSORY NOTE

 

	$[   ]	 

    Golden,
    Colorado

    Issue
    Date: NOVEMBer [  ], 2021

 

FOR
VALUE RECEIVED, Theralink Technologies, Inc., a Nevada Company (the “Company”), promises to pay to the order
of [  ] (the “Holder”) the principal amount of $[ ] (the “Principal Amount”) upon
the terms and subject to the conditions set forth herein (this “Note”). This Note is issued pursuant to a Securities
Purchase Agreement (the “Purchase Agreement”) between the Company and Holder and is one of a series of promissory
notes to be issued by the Company known as the 2021 Convertible Promissory Notes (collectively referred to as the “2021 Notes”),
all of which contain substantially similar terms. The 2021 Notes are intended to provide financing to the Company in anticipation of
a listing on a Qualified National Exchange (as defined below).

 

1.
Interest. Interest shall accrue on the outstanding Principal Amount, from the Issue Date until the date this Note is converted or
paid in full, at the rate of eight percent (8.0%) per annum simple interest (365 day basis) (the “Interest Rate”).
The Company will pay interest monthly, in arrears, in cash, on the first day of each month of each year following the Issue Date prior
to the maturity of this Note, or if any such day is not a Trading Day, on the next succeeding Trading Day (each, an “Interest
Payment Date”). Notwithstanding the immediately foregoing, at the option of the holder, interest may accrue on this Note
on a monthly basis. All accrued and unpaid interest shall be due and payable in full upon maturity, conversion or prepayment of this
Note, as provided herein. All cash payments received by the Holder in respect of this Note shall be applied first to accrued interest
and thereafter to the repayment of the outstanding Principal Amount.

 

2.
Maturity Date. If not sooner paid or converted according to the terms hereof, then on November 1, 2026, the Holder may demand
the outstanding Principal Amount plus all accrued and unpaid interest thereon be due and payable (the “Maturity Date”).
Upon the Maturity Date, in lieu of payment, the Holder or the Company may, upon notice to the other party, elect to convert the outstanding
Principal Amount plus accrued and unpaid interest under this Note into a number of shares of the Company’s common stock (the “Common
Stock”) equal to the quotient obtained by dividing:

 

(a)
the outstanding Principal Amount plus any accrued and unpaid interest under this Note (the “Conversion Amount”),
by

 

(b)
a per share price of $0.00366 (the “Conversion Price”).

 

    	-1-

    	 

    

 

3.
Prepayment. The Notes may be prepaid at any time after FINRA Approval (as defined below) at an amount equal to 110% of outstanding
principal balance of the Note and accrued and unpaid interest during the period from the Issue Date until the Maturity Date. In order
to prepay the Notes, the Company shall provide five (5) Trading Days prior written notice to the Holder, during which time the Holder
may convert the Notes in whole or in part at the Conversion Price.

 

4.
Covenants. The Company covenants and agrees that, until all of the obligations under this Note and the Purchase Agreement (as defined
below) have been fully performed and either paid in full in cash or converted into shares of Common Stock of the Company pursuant to
the terms hereof and this Note has been terminated, it will abide by the covenants set forth in the Purchase Agreement.

 

5.
Automatic Conversion. Upon the listing by the Company or the trading of the Common Stock on The Nasdaq Capital Market, The Nasdaq
Global Select Market, The Nasdaq Global Market, the New York Stock Exchange, the NYSE American, the NYSE Arca or any of their respective
successor entities (each a “Qualified National Exchange”), the Conversion Amount shall automatically be converted
into fully-paid and non-assessable shares of Common Stock. The number of shares of Company Stock to be issued upon the conversion contemplated
by this Section 5 shall be equal to the quotient obtained by dividing (i) the Conversion Amount by (ii) the lower of (a) the Conversion
Price (as adjusted as set forth herein); and (b) the average closing price of the Common Stock during the thirty (30) Trading Days immediately
preceding the date of the listing or trading of the Common Stock on a Qualified National Exchange.

 

6.
Optional Conversion. Subject in all respects to Section 15 of this Note, from and after FINRA Approval (as defined below),
the Conversion Amount, in whole or in part at any time and from time to time may be converted into shares of Company Stock at the election
of the Holder, in its sole discretion. The number of shares of Company Stock to be issued upon the optional conversion of Holder contemplated
by this Section 6 shall be equal to the quotient obtained by dividing (i) the Conversion Amount by (ii) the Conversion Price.
The Holder shall effect conversions by delivering to the Borrower a completed notice in the form attached hereto as Exhibit A
(a “Notice of Conversion”). The date on which a Notice of Conversion is delivered is the “Conversion
Date.” The Borrower shall deliver the applicable stock certificate to the Holder on or before the tenth (10th)
day after a Conversion Date. The Holder shall physically surrender this Note to the Borrower in connection with a conversion, whether
a partial conversion or a total conversion. In the event of a partial conversion, in order to reflect the reduction in the outstanding
principal amount of this Note and the reduction in the accrued and unpaid interest, the Borrower shall prepare and deliver to the Holder
a new Note, identical in all respects to the surrendered Note except for the principal amount outstanding reflected on the first page
hereof and the new Note shall have the amount of previously accrued interest that has not been converted reflected in the principal outstanding.
Such replacement Note (resulting from the partial conversion) shall be delivered to the Holder on or prior to the tenth (10th)
day after the applicable Conversion Date.

 

7.
Adjustment to Conversion Price. Except for any Exempt Issuance (as hereinafter defined), in the event the Company issues or sells
any securities including Options or Convertible Securities (or amends any outstanding securities of the Company), at an effective price
of, or with an exercise or conversion price of less than the Conversion Price, then upon such issuance or sale, the Conversion Price
shall be reduced to the sale price or the exercise or conversion price of the securities issued or sold. “Exempt Issuance”
shall mean any sale or issuance by the Company of its Common Stock or securities convertible into, exercisable for or exchangeable for
Common Stock in connection with (i) full or partial consideration in connection with a strategic merger, acquisition, consolidation or
purchase of the securities or assets of a corporation or other entity (or any division or business unit thereof), (ii) the Company’s
issuance of securities in connection with strategic supply, sale or license agreements and other partnering arrangements so long as such
issuances are not for the purpose of raising capital, (iii) the Company’s issuance of Common stock, restricted stock units or the
issuances or grants of Options to purchase Common Stock to employees, officers or directors, under an equity incentive plan adopted by
a majority of the non employee members of the Board of Directors of the Company; (iv) securities issued upon the exercise or exchange
of or conversion of any Convertible Securities issued and outstanding on the date of the issuance of Notes to securities holders of the
Company in exchange for other securities existing as of the date of this Note, (v) the conversion of any Series E, Series F, Series C-1
or Series C-2 Convertible Preferred Stock or (vi) any equity line of credit or similar agreement, if entered into with the consent of
Doug Mergenthaler. In case any shares of Common Stock, Convertible Securities or Options are issued in connection with the issue or sale
of other securities of the Company, together comprising one integrated transaction, each share of Common Stock underlying any such Convertible
Securities or Options shall be deemed to be one additional share of Common Stock for the purposes of determining the effective price
of the non-Exempt Issuance.

 

    	-2-

    	 

    

 

8.
Adjustment of Conversion Price upon Subdivision or Combination of Common Stock. If the Company at any time on or after the Issue
Date subdivides (by any stock split, stock dividend, recapitalization or other similar transaction) one or more classes of its outstanding
shares of Common Stock into a greater number of shares, the Conversion Price in effect immediately prior to such subdivision will be
proportionately reduced. If the Company at any time on or after the Issue Date combines (by any reverse split, recapitalization or other
similar transaction) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price
in effect immediately prior to such combination will be proportionately increased. Any adjustment pursuant to this Section 8 shall become
effective immediately after the effective date of such subdivision or combination.

 

9.
Acquisition. Immediately prior to the closing of a merger, share exchange, consolidation, acquisition of all or substantially all
of the assets or stock, reorganization or liquidation of the Company that results in the stockholders of the Company immediately prior
to such transaction owning less than 50% of the voting capital stock of the Company (or its successor or parent corporation) immediately
after the transaction or, in the case of a sale of assets or liquidation, the Company owning after the transaction less than substantially
all of the assets owned by the Company prior to the transaction (other than an issuance of equity securities for the primary purpose
of raising capital) (an “Acquisition”) that occurs prior to the satisfaction in full by the Company of all
outstanding Principal Amount and accrued but unpaid interest under this Note (including through the conversion of such amounts into capital
stock of the Company), the Holder may elect to either (i) convert all outstanding Principal Amount and accrued interest hereunder into
shares of Common Stock at the valuation of the Company on a per share basis as used in the Acquisition, or (ii) accelerate the Maturity
Date to the date of closing of the Acquisition transaction and thereupon the Company shall be obligated to pay Holder an amount equal
to the remaining Conversion Amount in full satisfaction of its obligations hereunder. In conjunction with such conversion in connection
with an Acquisition, the Holder shall execute all documentation required to be executed by other stockholders of Company in connection
with the Acquisition (the “Acquisition Agreements”), including without limitation escrow, indemnification and
other similar agreements.

 

10.
Participation in Future Financing.

 

(a)
From the date hereof until the date that is the 24 month anniversary of the Issue Date (or until 100% of the 2021 Notes is converted
into Common Stock, if earlier), upon any issuance by the Company of Common Stock or any security convertible into Common Stock for cash
consideration, indebtedness or a combination of units hereof in a transaction exempt from registration under the Securities Act (a “Subsequent
Financing”), each Holder shall have the right to participate in the Subsequent Financing up to an amount of the Subsequent
Financing equal to 10% of the Subsequent Financing for each $500,000 in aggregate Principal Amount of the 2021 Notes purchased by the
Holder (the “Participation Maximum”) on the same terms, conditions and price provided for in the Subsequent
Financing. At least five Trading Days prior to the closing of the Subsequent Financing, the Company shall deliver to each Holder a written
notice of its intention to effect a Subsequent Financing (“Pre-Notice”), which Pre-Notice shall ask such Holder
if it wants to review the details of such financing (such additional notice, a “Subsequent Financing Notice”).
Upon the request of a Holder, for a Subsequent Financing Notice, the Company shall promptly, but no later than two trading days after
such request, deliver a Subsequent Financing Notice to such Holder. The Subsequent Financing Notice shall describe in reasonable detail
the proposed terms of such Subsequent Financing, the amount of proceeds intended to be raised thereunder and the person or persons through
or with whom such Subsequent Financing is proposed to be effected and shall include a term sheet or similar document relating thereto
as an attachment.

 

    	-3-

    	 

    

 

(b)
Any Holder desiring to participate in such Subsequent Financing must provide written notice to the Company by not later than 5:30 p.m.
(New York City time) on the fifth trading day after such Holders have received the Subsequent Financing Notice that such Holder is willing
to participate in the Subsequent Financing, the amount of such Holder’s participation, and representing and warranting that such
Holder has such funds ready, willing, and available for investment on the terms set forth in the Subsequent Financing Notice. If the
Company receives no such notice from a Holder as of such fifth trading day, such Holder shall be deemed to have notified the Company
that it does not elect to participate.

 

(c)
The Company and each Holder agree that if any Holder elects to participate in the Subsequent Financing, the transaction documents related
to the Subsequent Financing shall not include any term or provision whereby such Holder shall be required to agree to any restrictions
on trading as to any of the Securities purchased hereunder or be required to consent to any amendment to or termination of, or grant
any waiver, release or the like under or in connection with, this Agreement, without the prior written consent of such Holder.

 

(d)
Notwithstanding anything to the contrary in this Section 10 and unless otherwise agreed to by such Holder, the Company shall either confirm
in writing to such Holder that the transaction with respect to the Subsequent Financing has been abandoned or shall publicly disclose
its intention to issue the securities in the Subsequent Financing, in either case in such a manner such that such Holder will not be
in possession of any material, non-public information, by the 10th business day following delivery of the Subsequent Financing Notice.
If by such 10th business day, no public disclosure regarding a transaction with respect to the Subsequent Financing has been made, and
no notice regarding the abandonment of such transaction has been received by such Holder, such transaction shall be deemed to have been
abandoned and such Holder shall not be deemed to be in possession of any material, non-public information with respect to the Company
or any of its Subsidiaries.

 

(e)
Notwithstanding the foregoing, this Section 10 shall not apply in respect of (i) an Exempt Issuance, or (ii) a public offering registered
with the SEC.

 

11.
Effect of Conversion. Upon conversion of this Note into shares of the Company’s Common Stock in accordance with the terms hereof,
and, if and as applicable, upon receipt by the Company of signature pages to the Acquisition Agreements executed by the Holder, the Company
shall promptly issue and deliver to the Holder (a) certificates for the shares issuable upon such conversion of this Note (“Conversion
Shares”) and (b) a capitalization table that reflects the Company’s Fully-Diluted Number of Shares as of the Conversion
Time (as defined below) certified as accurate and complete by a senior officer of the Company (if such information is not otherwise contained
in the Acquisition Agreements). Such conversion shall be deemed to have been made, in the case of conversion pursuant to Section 2,
as of the close of business on the Maturity Date or such earlier date as mutually agreeable to the Company and Holder; in the case of
a listing on a Qualified National Exchange, simultaneously with the completion of the initial listing and trading of the Common Stock
on a Qualified National Exchange; and in the case of an Acquisition, immediately prior to the closing of such Acquisition (in each case,
the “Conversion Time”). The Holder shall be treated for all purposes as the record holder of such Conversion
Shares as of the Conversion Time. No fractional Conversion Shares shall be issued in connection with any conversion of this Note, and
any fractional share shall be rounded up or down to the nearest whole share in lieu of any such fraction (and any fraction representing
one-half of a share shall be rounded up). The issuance of Conversion Shares to the Holder upon conversion of this Note in accordance
with its terms shall constitute satisfaction in full of the obligations of the Company under this Note.

 

    	-4-

    	 

    

 

12.
Limitation on Beneficial Ownership. The Company shall not effect the conversion of any of the Notes held by Lincoln Park Capital
Fund, LLP or Cavalry Fund I, LLP (each a “Restricted Holder”), and such Restricted Holder shall not have the
right to convert any of the Notes held by such Restricted Holder pursuant to the terms of this Note and any such conversion shall be
null and void and treated as if never made, to the extent that after giving effect to such conversion, such Restricted Holder would beneficially
own in excess of 4.99% (the “Maximum Percentage”) of the shares of Common Stock outstanding immediately after
giving effect to such conversion (which provision may be increased to a maximum of 9.9% by such Restricted Holder by written notice from
such Restricted Holder to the Company, which notice shall be effective 61 calendar days after the date of such notice). For purposes
of the foregoing sentence, the aggregate number of shares of Common Stock beneficially owned by such Restricted Holder shall include
the number of shares of Common Stock held by such Restricted Holder plus the number of shares of Common Stock issuable upon conversion
of the Notes with respect to which the determination of such sentence is being made, but shall exclude shares of Common Stock which would
be issuable upon (A) conversion of the remaining, nonconverted Notes beneficially owned by such Restricted Holder and (B) exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Company (including any convertible notes, convertible
preferred stock or warrants) beneficially owned by such Restricted Holder subject to a limitation on conversion or exercise analogous
to the limitation contained in this Section 12. For purposes of this Section 12, beneficial ownership shall be calculated in accordance
with Section 13(d) of the Securites and Exchange Act of 1934, as amended (the “1934 Act”) and the rules thereunder.
For purposes of determining the number of outstanding shares of Common Stock a Restricted Holder may acquire upon the conversion of such
Notes without exceeding the Maximum Percentage, such Restricted Holder may rely on the number of outstanding shares of Common Stock as
reflected in (x) the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K
or other public filing with the SEC, as the case may be, (y) a more recent public announcement by the Company or (z) any other written
notice by the Company or the Company’s transfer agent, if any, setting forth the number of shares of Common Stock outstanding (the
“Reported Outstanding Share Number”). Notwithstanding the preceding, the Restricted Holder may rely on the
transfer agent’s records if the Reported Outstanding Share Number is different than what the Company reports. If the Company receives
a Conversion Notice from a Restricted Holder at a time when the actual number of outstanding shares of Common Stock is less than the
Reported Outstanding Share Number, the Company shall notify such Restricted Holder in writing of the number of shares of Common Stock
then outstanding and, to the extent that such Conversion Notice would otherwise cause such Restricted Holder’s beneficial ownership,
as determined pursuant to this Section 12, to exceed the Maximum Percentage, such Restricted Holder must notify the Company of a reduced
number of shares of Common Stock to be purchased pursuant to such Conversion Notice. For any reason at any time, upon the written or
oral request of any Restricted Holder, the Company shall within one trading day confirm orally and in writing or by electronic mail to
such Restricted Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including such Notes, by such
Restricted Holder since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of shares
of Common Stock to a Restricted Holder upon conversion of such Notes results in such Restricted Holder being deemed to beneficially own,
in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under Section 13(d)
of the 1934 Act), the number of shares so issued by which such Restricted Holder’s beneficial ownership exceeds the Maximum Percentage
(the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and such Restricted Holder
shall not have the power to vote or to transfer the Excess Shares. For purposes of clarity, the shares of Common Stock issuable to a
Restricted Holder pursuant to the terms of this Note in excess of the Maximum Percentage shall not be deemed to be beneficially owned
by such Restricted Holder for any purpose including for purposes of Section 13(d) or Rule 16a-1(a)(1) of the 1934 Act. No prior inability
to convert such Notes pursuant to this paragraph shall have any effect on the applicability of the provisions of this paragraph with
respect to any subsequent determination of convertibility. The provisions of this paragraph shall be construed and implemented in a manner
otherwise than in strict conformity with the terms of this Section 12 to the extent necessary to correct this paragraph (or any portion
of this paragraph) which may be defective or inconsistent with the intended beneficial ownership limitation contained in this Section
12 or to make changes or supplements necessary or desirable to properly give effect to such limitation. The provisions of this Section
12 shall be of no further force or effect if the Restricted Holder participates in a subsequent transaction with the Company which results
in the Restricted Holder beneficially owning in excess of 4.99% of the number of shares of the Common Stock outstanding which shall include
securities convertible into Common Stock which do not contain a beneficial ownership limitation.

 

    	-5-

    	 

    

 

13.
Event of Default. If the Company (a) fails to pay when due any principal or interest payment on the due date hereunder, and such
payment shall not have been made within thirty (30) days of the Company’s receipt of the Holder’s written notice to the Company
of such failure to pay; (b) materially breaches any other covenant contained in this Note or the Purchase Agreement and such failure
continues for forty-five (45) days after the Company receives written notice of such material breach from the Holder; (c) voluntarily
files for bankruptcy protection or makes a general assignment for the benefit of creditors; or (d) is the subject of an involuntary bankruptcy
petition and such petition is not dismissed within ninety (90) days, then in any such case then the holders of Notes owning together
in excess of a majority of the aggregate Principal Amount of the Notes may, upon written notice to the Company, declare the 2021 Notes
(including this Note) in default and immediately due and payable in full. From that date forward, this Note shall bear interest at a
rate of the lower of ten percent (10%) per annum or the highest rate allowed by applicable law, until paid in full or converted.

 

14.
FINRA Penalty. If the Financial Industry Regulatory Authority, Inc. (“FINRA”) fails to approve the Company’s
name change to Theralink Technologies, Inc. and ticker symbol change (“FINRA Approval”) prior to November 1,
2022, then on such date the Company will pay a penalty fee equal to ten percent (10%) of the outstanding Principal Amount. If FINRA Approval
is not received prior to May 1, 2023, then on such date the Company will pay a penalty fee equal to eight percent (8%) of the outstanding
Principal Amount. Such fees will be added to the Principal Amount on their respective payment dates. If FINRA Approval is not received
prior to June 1, 2023, then any Holder may, upon five (5) business days written notice to the Company, declare the 2021 Notes (including
this Note) in default and immediately due and payable in full.

 

15.
Ranking. This Note and the other 2021 Notes shall rank pari passu as to the payment of principal and interest. The Holder agrees
that any payments or prepayments to the Holder and to the holders of the other 2021 Notes, whether principal, interest or otherwise,
shall be made pro rata among the Holder and the other holders of the 2021 Notes based upon the aggregate unpaid principal amount of this
Note and the other 2021 Notes. Notwithstanding the foregoing, this Note shall rank senior to any unsecured debt of the Company and to
any future promissory notes issued by the company, provided that this Note shall rank pari passu to any other 2021 Note.

 

16.
Restrictions on Transfer and IPO Lock-Up. As a condition to the conversion of this Note into equity securities of the Company, Holder
understands that the Conversion Shares are subject to restrictions on transfer under the Securities Act and applicable state securities
laws as well as other contractual restrictions that are in existence at the time of issuance of the Conversion Shares, including under
the Bylaws of the Company.

 

Holder
further understands and acknowledges that, notwithstanding anything to the contrary in this Note, the Note may not be converted into
shares of Common Stock and no Conversion Shares may be issued by the Company to Holder until FINRA Approval.

 

    	-6-

    	 

    

 

If
applicable, the Conversion Shares (unless registered under the Securities Act of 1933, as amended) will be stamped or imprinted with
a legend in substantially the following form:

 

THE
SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT
AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT
AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION
IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.

 

17.
No Rights as a Shareholder. Holder is not entitled, as a Holder in respect of this Note, to any rights as a shareholder of the Company
and Holder shall not be deemed the holder of the Conversion Shares or any other securities of the Company that may at any time be issuable
on the conversion of this Note for any purpose, nor will anything contained herein be construed to confer upon the Holder, as such, any
of the rights of a shareholder of the Company or any right to vote for the election of directors or upon any matter submitted to shareholders
at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of shares,
reclassification of shares, change of par value, consolidation, merger, conveyance, or otherwise) or to receive notice of meetings, or
to receive dividends or subscription rights or otherwise until this Note has been converted and the Conversion Shares issuable upon the
conversion hereof have been issued or become deliverable, as provided herein.

 

18.
Subordination. By accepting this Note, the Holder agrees that all payments on account of the indebtedness, liabilities and other
obligations of the Company to the Holder, including, without limitation, all amounts of principal, interest accrued hereon, and all other
amounts payable by the Company to the Holder under this Note or in connection herewith shall be subordinated and subject in right of
payment, to the extent and manner set forth herein, to the prior payment in full in cash or cash equivalents of any existing or future
Senior Indebtedness of the Company. “Senior Indebtedness” shall mean any (i) indebtedness, liabilities and
other obligations of the Company or with respect to which the Company is a guarantor, to banks, insurance companies or other lending
or thrift institutions regularly engaged in the business of lending money, whether or not secured, (ii) indebtedness, liabilities and
other obligations of the Company under any line of credit or revolving credit facility, (iii) any deferrals, renewals or extensions or
any debentures, notes or other evidence of indebtedness issued in exchange for such Senior Indebtedness and (iv) the Company’s
2021 Convertible Secured Promissory Note issued May 12, 2021. Upon request from the Company, each Holder will agree to execute and deliver
a subordination agreement, in a form reasonably acceptable to any banks, insurance companies or other lending or thrift institutions
holding Senior Indebtedness, subordinating the Holder’s interests under this Note to the interests of any banks, insurance companies
or other lending or thrift institutions holding Senior Indebtedness.

 

Upon
any receivership, insolvency, assignment for the benefit of creditors, bankruptcy, reorganization, or arrangement which creditors (whether
or not pursuant to bankruptcy or other insolvency laws), sale of all or substantially all of the assets, dissolution, liquidation, or
any other marshaling of the assets and liabilities of the Company or in the event this Note shall be due and payable (including upon
maturity), (i) no amount shall be paid by the Company, whether in cash or property in respect of the principal of or interest on this
Note at the time outstanding, unless and until the full amount of any Senior Indebtedness then outstanding shall be paid in full, and
(ii) no claim or proof of claim shall be filed with the Company by or on behalf of the holder of this Note which shall assert any right
to receive any payments in respect of the principal of and interest on this Note except subject to the payment in full all of the Senior
Indebtedness then outstanding.

 

    	-7-

    	 

    

 

If
an event of default has occurred with respect to any Senior Indebtedness, permitting the holder thereof to accelerate the maturity thereof,
then unless and until such event of default shall have been cured or waived or shall have ceased to exist, or all Senior Indebtedness
shall have been paid in full, no payment shall be made in respect of the principal of or interest on this Note and no action shall be
taken to collect on any of the principal of or interest on this Note. For purposes of clarity, the conversion of this Note into Conversion
Shares or any other equity security of the Company shall not be deemed a payment for purposes of this Section 9 and shall be expressly
permitted without regard to the Senior Indebtedness.

 

19.
Notices. All notices provided for in this Note shall be in writing and deemed to be duly given upon (a) delivery via electronic mail
(provided no notice of failure of delivery is received by the sender) or in person, (b) four business days after deposit in the United
States mail, certified or registered, postage prepaid and (c) one business day after deposit with a reputable, national overnight courier
service for next business day delivery with all charges prepaid. Notices shall be sent, with respect to the Company, to the address set
forth below, and with respect to Holder, to the address set forth on the signature page hereto or at such other address as such party
may designate by ten (10) days advance written notice to the other party given in the foregoing manner:

 

	If
    to Company:	 	Theralink
    Technologies, Inc.

    15000 W. 6th Ave., #400

    Golden,
    CO 80401

    Attn: Mick Ruxin, M.D. CEO

    Email: mick@theralink.com

     

	With
    copy to:	 	K&L
    Gates LLP

    200 S. Biscayne Blvd., Ste. 3900

    Miami, Florida 33131

    Attn: Clayton Parker, Esq.

    Email:
    clayton.parker@klgates.com

 

20.
Governing Law. This Note, and any disputes arising under this Note, will be governed by and construed in accordance with the laws
of the State of Nevada, without giving effect to any conflict of laws principle to the contrary. The Company and the Holder agree that
the state and federal courts located in Nevada will have exclusive jurisdiction over any dispute between them arising out of this Note.

 

21.
Assignment. The rights and obligations of the Company and the Holder shall be binding upon and shall inure to the benefit of their
successors, assigns and transferees. Holder may not assign or otherwise transfer this Note without the prior written consent of the Company.

 

22.
Waiver and Amendment. The provisions of this Note may be amended or waived only upon the written consent of the Company and the Holder.

 

23.
Collection Costs. The Company agrees to pay all costs and expenses, including without limitation reasonable attorneys’ fees,
incurred by the Holder in any action brought to enforce the terms of this Note and/or to collect this Note, and in any appeal thereof.

 

24.
Headings. Headings used in this Note have been included for convenience and ease of reference only, and will not in any manner influence
the construction or interpretation of any provision of this Note.

 

25.
Only Company Liable. In no event shall any stockholder, officer, director or employee of the Company be liable for any amounts due
or payable pursuant to this Note.

 

26.
Expenses. Each of the Company and the Holder will bear its own expenses associated with the negotiation and execution of this Note.

 

27.
Counterparts. The Note may be executed in two counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument.

 

*
* * *

 

    	-8-

    	 

    

 

The
Company has caused this Convertible Promissory Note to be signed by its duly authorized officer and dated the day and year first above
written.

 

	THERALINK
    TECHNOLOGIES, INC.	 
	 	 	 
	By:	 	 
	Name:	Mick
    Ruxin, M.D.	 
	Title:	Chief
    Executive Officer	 

 

	AGREED
    AND ACCEPTED:	 
	 	 
	[INVESTOR]	 
	 	 	 
	By:	        	 
	Name:	 	 
	Title:	 	 
	 	 	 
	Address: 	 
	Email:	 	 

 

SIGNATURE
PAGE TO CONVERTIBLE PROMISSORY NOTE

 

    	 

    	 

    

 

EXHIBIT
A

NOTICE
OF CONVERSION

(To
be executed by the Holder in order to convert this Note)

 

To:
Theralink Technologies, Inc.

15000 W. 6th Ave., #400

Golden,
CO 80401

Attn:
Chief Executive Officer

 

The
undersigned hereby irrevocably elects to convert $ of the outstanding principal and/or accrued interest of the above Note into shares
of Common Stock of Theralink Technologies, Inc., according to the conditions stated therein, as of the Conversion Date written below.

 

Conversion
Date:

Applicable
Note Conversion Price:

Signature:

Name:

Address:

	Amount to
  be converted:	$
	Amount of
  Note unconverted:	$

		

Note
Conversion Price per share:

Number
of shares of Common Stock to be issued:

Please
issue the shares of Common Stock in the following name and to the following address:

 

SIGNATURE
PAGE TO CONVERTIBLE PROMISSORY NOTEExhibit
4.2

 

NEITHER
THIS WARRANT NOR THE SECURITIES FOR WHICH THIS WARRANT IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION
OR THE SECURITIES COMMISSION OF ANY STATE, IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS, AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR
TO SUCH EFFECT, THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY.

 

COMMON
STOCK PURCHASE WARRANT

 

THERALINK
TECHNOLOGIES, inc.

 

	Warrant
    Shares: [  ]	 	Issue
    Date: November [  ], 2021

 

THIS
COMMON STOCK PURCHASE WARRANT (this “Warrant”) certifies that, for value received, [  ] (the “Holder”)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the
Issue Date and upon the CUSIP eligibility of the Warrant Shares (as defined below) (the “Initial Exercise Date”) and
on or prior to the close of business on the Termination Date (as defined below) but not thereafter, to subscribe for and purchase from
Theralink Technologies, Inc., a Nevada corporation (the “Company”), of up to [ ] shares (subject to adjustment hereunder,
the “Warrant Shares”) of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”).
This Warrant is being issued in connection with the Securities Purchase Agreement, dated November [ ], 2021 by and between the
Company and the Holder pursuant to which the Holder is purchasing from the Company a convertible promissory note.

 

Section
1. Exercise; Termination Date.

 

a)
Exercise of Warrant. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time
or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office
or agency of the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on
the books of the Company) of a duly executed facsimile copy of the Notice of Exercise Form annexed hereto as Annex A; and, within
three (3) Business Days of the date said Notice of Exercise is delivered to the Company, the Company shall have received payment of the
aggregate Exercise Price of the shares thereby purchased by wire transfer or cashier’s check drawn on a United States bank. Notwithstanding
anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder
has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3) Business Days of the date the final Notice of Exercise is delivered
to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares available
hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the
applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant Shares
purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise Form within two (2) Business
Days of receipt of such notice. In the event of any dispute or discrepancy, the records of the Holder shall be controlling and determinative
in the absence of manifest error. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason
of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares
available for purchase hereunder at any given time may be less than the amount stated on the face hereof. As used herein, “Business
Day” means any day except Saturday, Sunday or any other day on which commercial banks located in the State of Nevada are authorized
or required by law to be closed for business.

 

b)
Exercise Price. The exercise price (the “Exercise Price”) of this Warrant shall be $0.00366 per Warrant Share,
subject to adjustment hereunder.

 

    	1

    	 

    

 

c)
Mechanics of Exercise.

 

i.
Delivery of Certificates Upon Exercise. Certificates for the Warrant Shares purchased or exercised hereunder shall be transmitted
by the Company’s transfer agent to the Holder by crediting the account of the Holder’s broker with the Depository Trust Company
through its Deposit Withdrawal Agent Commission (“DWAC”) system if the Company is then a participant in such system
and there is an effective registration statement permitting the resale of the Warrant Shares and otherwise by physical delivery to the
address specified by the Holder in the Notice of Exercise within three (3) Business Days from the delivery to the Company of the Notice
of Exercise Form, surrender of this Warrant (if required), and payment of the aggregate Exercise Price (unless cashless exercise is utilize)
as set forth above (the “Warrant Share Delivery Date”). This Warrant shall be deemed to have been exercised on the
date the Exercise Price is received by the Company (or notice of cashless exercise is received). The Warrant Shares shall be deemed to
have been issued, and Holder or any other person so designated to be named therein shall be deemed to have become a holder of record
of such shares for all purposes, as of the date the Warrant has been exercised by payment to the Company of the Exercise Price and all
taxes required to be paid by the Holder, if any, pursuant to Section 1(c)(v) prior to the issuance of such shares, have been paid.

 

ii.
Delivery of New Warrants Upon Exercise. If this Warrant shall have been exercised in part, the Company shall, at the request of
a Holder and upon surrender of this Warrant, at the time of delivery of the certificate or certificates representing Warrant Shares,
deliver to Holder a new Warrant evidencing the rights of Holder to purchase the unpurchased Warrant Shares called for by this Warrant,
which new Warrant shall in all other respects be identical with this Warrant.

 

iii.
Rescission Rights. If the Company fails to cause the Company’s transfer agent to transmit to the Holder a certificate or
the certificates representing the Warrant Shares pursuant to Section 1(c)(i) by the Warrant Share Delivery Date, then, the Holder
will have the right to rescind such exercise.

 

iv.
No Fractional Shares or Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise
of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company
shall, at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied
by the Exercise Price or round up to the next whole share.

 

v.
Charges, Taxes and Expenses. Issuance of certificates for Warrant Shares shall be made without charge to the Holder for any issue
or transfer tax or other incidental expense in respect of the issuance of such certificate, all of which taxes and expenses shall be
paid by the Company, and such certificates shall be issued in the name of the Holder or in such name or names as may be directed by the
Holder; provided, however, that in the event certificates for Warrant Shares are to be issued in a name other than the
name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment Form attached hereto duly executed
by the Holder, and such other documentation as the Company may require regarding the investor status of the assignee, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto.

 

vi.
Closing of Books. The Company will not close its stockholder books or records in any manner which prevents the timely exercise
of this Warrant, pursuant to the terms hereof.

 

    	2

    	 

    

 

d)
Termination Date. This Warrant shall be exercisable from the Initial Exercise Date until November 1, 2026 (the “Termination
Date”).

 

Section
2. Certain Adjustments.

 

a)
Fundamental Transaction. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or
more related transactions effects any merger or consolidation of the Company with or into another person, (ii) the Company, directly
or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of
its assets in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer
(whether by the Company or another person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange
their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock,
(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization
of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for
other securities, cash or property, (v) the Company, directly or indirectly, in one or more related transactions consummates a stock
or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off
or scheme of arrangement) with another person or group of persons whereby such other person or group acquires more than 50% of the outstanding
shares of Common Stock (not including any shares of Common Stock held by the other person or other persons making or party to, or associated
or affiliated with the other persons making or party to, such stock or share purchase agreement or other business combination) (each
a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right
to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental
Transaction, at the option of the Holder, the number, class, and series of shares of stock of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate Consideration”)
receivable as a result of such Fundamental Transaction by a holder of the number of shares of Common Stock for which this Warrant is
exercisable immediately prior to such Fundamental Transaction. For purposes of any such exercise, the determination of the Exercise Price
shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders
of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the
“Successor Entity”) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction
Documents in accordance with the provisions of this Section 2(a) pursuant to written agreements in form and substance reasonably
satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at
the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written
instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital
stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise
of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an
exercise price which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value
of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of
shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior
to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon
the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after
the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction Documents referring to the “Company”
shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations
of the Company under this Warrant and the other Transaction Documents with the same effect as if such Successor Entity had been named
as the Company herein.

 

    	3

    	 

    

 

b)
Equity Issuances.
Except for any Exempt Issuance (as hereinafter defined), in the event the Company issues or sells any securities including options or
convertible securities (or amends any outstanding securities of the Company), at an effective price of, or with an exercise or conversion
price of less than the Exercise Price, then upon such issuance or sale, the Exercise Price shall be reduced to the sale price or the
exercise or conversion price of the securities issued or sold. “Exempt Issuance” shall mean any sale or issuance by the Company
of its Common Stock or securities convertible into, exercisable for or exchangeable for Common Stock in connection with (i) full or partial
consideration in connection with a strategic merger, acquisition, consolidation or purchase of the securities or assets of a corporation
or other entity (or any division or business unit thereof), (ii) the Company’s issuance of securities in connection with strategic
supply, sale or license agreements and other partnering arrangements so long as such issuances are not for the purpose of raising capital,
(iii) the Company’s issuance of Common Stock, restricted stock units or the issuances or grants of options to purchase Common Stock
to employees, officers or directors, under an equity incentive plan adopted by a majority of the non employee members of the Board of
Directors of the Company; (iv) securities issued upon the exercise or exchange of or conversion of any convertible securities issued
and outstanding on the date of the issuance of Series E to securities holders of the Company in exchange for other securities existing
as of the date of this Warrant, (v) the conversion of any Series E, Series C-1 Convertible Preferred Stock and Series C-2 Convertible
Preferred Stock or (vi) any equity line of credit or similar agreement, if entered into with the consent of Doug Mergenthaler. In case
any shares of Common Stock, convertible securities or options are issued in connection with the issue or sale of other securities of
the Company, together comprising one integrated transaction, each share of Common Stock underlying any such convertible securities or
options shall be deemed to be one additional share of Common Stock for the purposes of determining the effective price of the non-Exempt
Issuance.

 

c)
Stock Dividends and Splits. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise
makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares
of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged, subject to the limitation on fractional shares in Section 2(d)(iv). Any adjustment made pursuant to this Section
2(b) shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend
or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or re-classification.

 

d)
Calculations. All calculations under this Section 2 shall be made to the nearest cent or the nearest 1/100th of a share,
as the case may be.

 

e)
Notice to Holder.

 

i.
Adjustment to Exercise Price. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 2, the
Company shall promptly deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and
setting forth a brief statement of the facts requiring such adjustment.

 

    	4

    	 

    

 

ii.
Notice to Allow Exercise by Holder. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on
the Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of
capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with
any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of all or
substantially all of the assets of the Company, of any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number of email address as it shall appear upon the Warrant Register of the Company, at least five (5) calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. The Holder is entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice.

 

f)
Holder’s Exercise Limitations. Lincoln Park Capital, LLC and Cavalry Fund I LP (each a “Restricted Holder”)
shall not have the right to exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after
giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Restricted Holder (together with
the Restricted Holder’s Affiliates, and any other Persons acting as a group together with the Restricted Holder or any of the Restricted
Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial
Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned
by the Restricted Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon
exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock
which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Restricted
Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of
any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion
or exercise analogous to the limitation contained herein beneficially owned by the Restricted Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated
in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Restricted Holder that the Company is not representing to the Restricted Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act. The Restricted Holder acknowledges and agrees that it is solely responsible for any schedules required to be filed
in accordance therewith. To the extent that the limitation contained in this Section 2(e) applies, the determination of whether
this Warrant is exercisable (in relation to other securities owned by the Restricted Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Restricted Holder, and the submission
of a Notice of Exercise shall be deemed to be the Restricted Holder’s determination of whether this Warrant is exercisable (in
relation to other securities owned by the Restricted Holder together with any Affiliates and Attribution Parties) and of which portion
of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation. Notwithstanding anything to the contrary,
the Company shall have no obligation to verify or confirm the accuracy of the Restricted Holder’s determination. In addition, a
determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and
the rules and regulations promulgated thereunder. For purposes of this Section 2(e), in determining the number of outstanding
shares of Common Stock, a Restricted Holder may rely on the number of outstanding shares of Common Stock as reflected in (A) the Company’s
most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company
or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.
Upon the written or oral request of a Restricted Holder, the Company shall within three Trading Days confirm orally and in writing to
the Restricted Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by
the Restricted Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common
Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock
outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Restricted
Holder and the provisions of this Section 2(e) shall continue to apply. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph (or
any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make
changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.

 

    	5

    	 

    

 

Section
3. Transfer of Warrant.

 

a)
Transferability. Subject to compliance with any applicable securities laws and the reasonable conditions and documentation required
by the Company, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole
or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment
of this Warrant substantially in the form attached hereto as Annex B (the “Assignment Form”), duly executed
by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon
such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee
or assignees, as applicable, and in the denomination or denominations specified in such instrument of assignment, and shall issue to
the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. The
Warrant, if properly assigned, may be exercised by a new holder for the purchase of Warrant Shares without having a new Warrant issued.

 

b)
New Warrants. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of
the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by
the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to any transfer which may be involved in such
division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be
divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Initial Exercise
Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.

 

c)
Warrant Register. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the
“Warrant Register”), in the name of the record Holder hereof from time to time. The Company may deem and treat the
registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder,
and for all other purposes, absent actual notice to the contrary.

 

Section
4. Miscellaneous.

 

a)
No Rights as Stockholder Until Exercise. This Warrant does not entitle the Holder to any voting rights or other rights as a stockholder
of the Company prior to the exercise hereof as set forth in Section 1(a).

 

b)
Loss, Theft, Destruction or Mutilation of Warrant. The Company covenants that upon receipt by the Company of evidence reasonably
satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares,
and in case of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant,
shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the
Company will make and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant
or stock certificate.

 

c)
Saturdays, Sundays, Holidays, etc. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.

 

    	6

    	 

    

 

d)
Authorized Shares. The Company covenants that, during the period the Warrant is outstanding, it will reserve, from its authorized
and unissued Common Stock, a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase
rights under this Warrant. The Company further covenants that its issuance of this Warrant shall constitute full authority to its officers
who are charged with the duty of executing stock certificates to execute and issue the necessary certificates for the Warrant Shares
upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to
assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements
of the business market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares which may be issued upon
the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant,
be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in
respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such issue).

 

e)
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined
by applying the laws of the State of Nevada, without regard to its conflicts of laws provisions.

 

f)
Restrictions. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant will have restrictions
upon resale imposed by state and federal securities laws unless (i) such Warrant Shares are registered; or (ii) the resale of the Warrant
Shares satisfies an exemption from registration under the Securities Act.

 

g)
Nonwaiver and Expenses. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall
operate as a waiver of such right or otherwise prejudice Holder’s rights, powers or remedies, notwithstanding the fact that all
rights hereunder terminate on the Termination Date. If the Company willfully and knowingly fails to comply with any provision of this
Warrant, which results in any material damages to the Holder, the Company shall pay to Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys’ fees, including those of appellate proceedings,
incurred by Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

 

h)
Notices. All notices and other communications from the Company to the Holder of this Warrant shall be sent by electronic transmission
or overnight courier or shall be mailed by first class registered or certified mail, postage prepaid, at such address as may have been
furnished to the Company in writing by such Holder. All such notices and communications shall, when mailed, be effective when deposited
in the mails and, when sent by electronic transmission or overnight courier, delivered, be effective when received.

 

i)
Limitation of Liability. No provision hereof, in the absence of any affirmative action by Holder to exercise this Warrant to purchase
Warrant Shares, and no enumeration herein of the rights or privileges of Holder, shall give rise to any liability of Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.

 

j)
Successors and Assigns. Subject to applicable federal and state securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of all Holders from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.

 

k)
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and
the Holder.

 

l)
Severability. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid
under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall
be ineffective to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining
provisions of this Warrant.

 

m)
Headings. The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed
a part of this Warrant.

 

[SIGNATURE
PAGE FOLLOWS]

 

    	7

    	 

    

 

IN
WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above
indicated.

 

	 	THERALINK
    TECHNOLOGIES, INC.
	 	 
	 	By	 
	 	Name:	Mick
    Ruxin
	 	Title:	Chief
    Executive Officer

 

    	 

    	 

    

 

ANNEX
A

 

NOTICE
OF EXERCISE

 

To:
THERALINK TECHNOLOGIES, INC.

 

(1)
The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only
if exercised in full), and

 

(2)
Payment shall take the form of lawful money of the United States:

 

(3)
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned or in such other name as is
specified below:

 

	 	 	 

 

The
Warrant Shares shall be delivered to the following DWAC Account Number or by physical delivery of a certificate to:

 

	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

(4)
Accredited Investor. The undersigned is an “accredited investor” as defined in Rule 501(a) of Regulation D, promulgated
under the Securities Act of 1933, as amended.

 

[SIGNATURE
OF HOLDER]

 

Name
of Investing Entity:

___________________________________________________________________________

Signature
of Authorized Signatory of Investing Entity:

_____________________________________________________

Name
of Authorized Signatory:

_______________________________________________________________________

Title
of Authorized Signatory:

________________________________________________________________________

Date:

___________________________________________________________________________________________

 

    	 

    	 

    

 

ANNEX
B

 

ASSIGNMENT
FORM

 

(To
assign the foregoing warrant, execute

this form and supply required information.

Do not use this form to exercise the Warrant.)

 

FOR
VALUE RECEIVED, [____] all of or [_______] shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

_______________________________________________
whose address is

 

_______________________________________________________________.

 

_______________________________________________________________

 

	 	 	Dated:
    ______________, ___________
	 	 	 
	 	Holder’s
    Signature:	_______________________________
	 	 	 
	 	Holder’s
    Address:	_______________________________
	 	 	 
	 	 	_______________________________

 

Signature
Guaranteed: ___________________________________________

 

NOTE:
The signature to this Assignment Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement
or any change whatsoever, and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary
or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00336-of-00352.parquet"}]]